drugset
drugset / Trial / NCT04771611

COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications

NCT04771611 ↗

Phase 2 Completed 55 enrolled James L. Kirkland, MD, PhD
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test whether Fisetin, a senolytic drug can assist in the reduction of complications in patients with COVID-19 infection.

Timeline

Start
2021-07-14
Primary completion
2022-09-27
Completion
2022-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Fisetin Small molecule 20 mg/kg Oral

Indications

COVID-19